Diabetic macular edema (DME) is a common complication of diabetes and the leading cause of vision loss among adults aged 50 years and older. DME can be caused by increased blood sugar levels or high blood pressure. It is characterized by swelling of the retina, which can lead to blurred vision, distorted vision, and sometimes blindness.

Which Drug is the Best for DME?

In a new study, researchers included 4,854 people with diabetic retinopathy who were randomized to receive one of three treatments: Aflibercept (Eylea), an antibody that binds to vascular endothelial growth factor A (VEGF-A) and blocks its ability to cause blood vessel growth. Intravitreal ranibizumab (Lucentis), a monoclonal antibody that binds to VEGF-A and blocks its ability to cause blood vessel growth, or bevacizumab (Avastin), a humanized monoclonal antibody that binds to VEGF-A and blocks its ability to cause blood vessel growth.

The researchers found that all three drugs improved vision and reduced the risk of vision loss. However, those who received aflibercept had significantly better vision at one year and more improvement in vision over time than those who received ranibizumab or bevacizumab.

The findings were consistent across subgroups of people with different degrees of vision loss, including people with moderate vision loss or worse. “Our study shows that all three treatments are effective in improving vision and reducing the risk of vision loss in people with diabetic retinopathy,” said study author Dr. Jeffrey D. Goldberg, director of the Joslin Center for Clinical Research.

“However, people with more severe vision loss benefit most from aflibercept. Aflibercept is also the only treatment that can help prevent vision loss.” “Aflibercept is a new drug that has been approved for the treatment of diabetic macular edema. It is the first drug that has been shown to improve vision in people with diabetic macular edema,” said lead author Dr. Paul M. Schuman, associate professor of ophthalmology at the University of Michigan.

“It is important to note that the patients in our study had mild-to-moderate diabetic retinopathy, which is less severe than the disease that is usually treated with laser therapy or vitrectomy. Therefore, we do not know whether this drug would be effective in patients with more severe diabetic retinopathy.”

The researchers found that all three drugs improved vision and reduced the risk of vision loss. However, those who received aflibercept had significantly better vision at one year and more improvement in vision over time than those who received ranibizumab or bevacizumab.

“Our study shows that all three treatments are effective in improving vision and reducing the risk of vision loss in people with diabetic retinopathy,” said study author Dr. Jeffrey D. Goldberg, director of the Joslin Center for Clinical Research. “However, people with more severe vision loss benefit most from aflibercept. Aflibercept is also the only treatment that can help prevent vision loss.

What is Aflibercept?

Aflibercept is a recombinant antibody that is used to reduce the enlargement of abnormal vessels in the eye. It is used to treat wet AMD when the disease is in the advanced stages and cannot be controlled by other treatments.

The drug is injected into the eye every 4 weeks. It is approved for the treatment of wet AMD and diabetic macular edema (DME) in people with diabetic retinopathy.

What Is the Most Common Side Effect of Aflibercept?

The most common side effects of aflibercept are eye pain, blurred vision, headache, and increased intraocular pressure. These side effects are usually mild and go away within a few days.

How Does Aflibercept Work?

Aflibercept works by binding to VEGF-A, which is a protein that helps blood vessels grow. It then blocks the activity of VEGF-A, which stops the growth of abnormal blood vessels in the eye.

Why Was This Study Done?

This study was done to determine whether aflibercept is more effective than other anti-VEGF drugs in improving vision in people with diabetic retinopathy. The researchers also wanted to see if there were any differences in the types of side effects experienced by people who received aflibercept compared to those who received ranibizumab or bevacizumab.

What is Ranibizumab?

Ranibizumab, also known by the brand name Lucentis, is a prescription medication used to treat the symptoms of wet age-related macular degeneration (AMD) in adult patients.

It is a humanized monoclonal antibody that binds to and inhibits the activity of vascular endothelial growth factor (VEGF).

What is Bevacizumab?

Bevacizumab, also known by the brand name Avastin, is a prescription medication used to treat wet AMD in adult patients. It is a humanized monoclonal antibody that binds to and inhibits the activity of VEGF.

What Are the Most Common Side Effects of Ranibizumab or Bevacizumab?

The most common side effects of ranibizumab or bevacizumab are eye pain, blurred vision, headache, increased intraocular pressure, and allergic reactions. These side effects usually go away within a few days.

How Does Ranibizumab or Bevacizumab Work?

Ranibizumab or bevacizumab works by binding to VEGF-A, which is a protein that helps blood vessels grow. It then blocks the activity of VEGF-A, which stops the growth of abnormal blood vessels in the eye.

How Does Laser Help Diabetic Macular Edema?

Laser therapy is a minimally invasive technique that has been used for many years to treat patients with macular edema. It uses a laser beam that is focused on the retina to deliver energy to the retinal pigment epithelium (RPE).

What Are the Most Common Side Effects of Laser Therapy?

Side effects of laser therapy include blurred vision, floaters, light sensitivity, and a red or yellowish appearance of the eye. These side effects usually go away within a few days.

How Do I Know if Laser Is Right for Me?

If you have diabetic macular edema, your doctor will probably recommend laser therapy. Your doctor may also recommend laser therapy if you have diabetic retinopathy or diabetic macular degeneration.

How Often Should I Have Laser Therapy?

You should have laser therapy every 2 to 4 weeks until your edema goes away. Your doctor will guide you when you would follow-up. Laser therapy is an alternative to surgery and steroid injections. It is also used as a supplement to other types of therapy. Laser therapy is effective in treating most types of edema.

What Are the Benefits of Laser Therapy?

Laser therapy can help reduce your risk of developing vision loss from diabetic macular edema. Laser therapy can treat the condition and reduce your risk of worsening vision. Laser therapy is an effective treatment for diabetic macular edema. The laser energy delivered to the retina affects the underlying tissue, reducing the swelling.

The best way to prevent diabetic retinopathy and diabetic macular edema is to prevent or control your diabetes. Click here to know more.

Comments

comments